Cure8 research brief
If you're living with Crohn's disease, earlier and better diagnosis (for example, more cross-sectional imaging) may partly explain falling surgery rates over time. This study suggests system-level diagnostic improvements can reduce the need for surgery independent of increased biologic prescribing.
Adult patients with Crohn's disease, gastroenterology clinicians, IBD researchers, and health systems planners interested in diagnostics and surgical outcomes.
This is an observational, multicenter analysis of 1,354 Chinese Crohn's disease patients (median follow-up ~6 years) using registry data from 2000–2024. The study describes trends in imaging use, surgically diagnosed cases, treatments, and surgical outcomes and uses time-dependent Cox models and propensity-score matching to explore associations.
The central finding is an association between improved diagnostic pathways (large increase in cross-sectional imaging and fewer surgically diagnosed patients) and lower surgical rates over time.
The paper reports no independent association between biologic use and reduced surgery risk in their models; because this is observational data, this should not be interpreted as proof that biologics do not reduce surgery in all settings.
Observational registry data can identify associations but cannot prove causation. Changes in other care elements, patient selection for biologics, and unmeasured factors could affect surgical rates.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.
Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...
